ENTITY
Nektar Therapeutics

Nektar Therapeutics (NKTR US)

8
Analysis
Health CareUnited States
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is comprised of early to late stage drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.
more
Refresh
bearishPureTech Health
10 Oct 2022 18:28

PureTech Health (PRTC LN): Possible Combination with Nektar Is Just a Defensive Move

Puretech shares gained ~20% since my bullish insight on the company on May 31. Investors should book profit amid uncertainty regarding possibility...

Logo
199 Views
Share
13 Dec 2021 00:57

Nektar Therapeutics (NKTR US): A Good Buying Option in Immuno-Oncology Therapeutic Area

Nektar presented favorable clinical data for its lead candidate, bempeg at a global healthcare conference recently. Bempeg, a potential blockbuster...

Logo
243 Views
Share
05 Dec 2021 12:13

S&P500 Index Rebalance: Migrations Across the Indices

There are 3 migrations from the S&P400 to the S&P500 and vice versa and another 3 migrations from the S&P600 to the S&400 and vice versa. The one...

Logo
479 Views
Share
bearishS&P 500 INDEX
20 May 2020 07:34

U.S. Equity Strategy: Round Trip Back To Resistance

Our base case continues to be for near-term consolidation while the market determines the implications of states’ reopening (i.e., the...

Logo
199 Views
Share
15 Feb 2018 23:40

Nektar: New Pathways To Smarter Deals?

Nektar Therapeutics (NKTR US) 's share price soared 11.02% to $84 on Wednesday after it announced the world's largest ever biotech deal with...

Logo
234 Views
Share
x